Maxiflo 125/6mcg Inhaler 120MDI

Maxiflo 125 6mcg Inhaler 120mdi contains Fluticasone Propionate and Formoterol, a fixed-dose inhaled combination medicine used in the long-term management of obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Fluticasone Propionate is an inhaled corticosteroid that reduces airway inflammation, while Formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle and improves airflow. Together, they help control breathing symptoms, reduce exacerbations, and improve overall lung function. This combination is commonly prescribed as maintenance therapy and should be used regularly as advised by your doctor.

Maxiflo 125 6mcg Inhaler 120mdi combines Fluticasone Propionate, a potent inhaled corticosteroid (ICS), with Formoterol fumarate, a long-acting selective beta-2 adrenergic agonist (LABA), to provide dual control of airway inflammation and bronchoconstriction in chronic respiratory disease.

Fluticasone Propionate acts locally in the lungs by suppressing inflammatory processes that contribute to airway narrowing, mucus production, and bronchial hyperresponsiveness. It inhibits inflammatory cytokines, reduces eosinophilic infiltration, and decreases airway swelling over time. Because of its strong topical anti-inflammatory activity and low systemic absorption at recommended doses, it is widely used in persistent asthma management.

Formoterol is a long-acting bronchodilator that selectively stimulates beta-2 receptors in bronchial smooth muscle. This leads to relaxation of airway muscles and sustained bronchodilation for up to 12 hours or longer. Formoterol has a relatively rapid onset of action compared with some other long-acting bronchodilators, making it effective in maintaining airway patency and symptom control.

The combination of an inhaled corticosteroid and long-acting bronchodilator provides better control than either medicine alone in many patients with persistent asthma or COPD. It reduces symptom frequency, night-time awakenings, and exacerbation risk while improving exercise tolerance and pulmonary function.

Maxiflo 125 6mcg Inhaler 120mdi is available in inhaler form and must be used regularly even when symptoms are controlled, as it is intended for maintenance rather than immediate emergency relief.

The uses of Maxiflo 125 6mcg Inhaler 120mdi are as follows:

Bronchial Asthma

Maintenance treatment in persistent asthma requiring both anti-inflammatory and bronchodilator therapy.

Chronic Obstructive Pulmonary Disease (COPD)

Long-term symptom control in selected COPD patients.

Prevention of Asthma Exacerbations

Helps reduce frequency of flare-ups.

Control of Night-time Respiratory Symptoms

Improves overnight symptom control in chronic airway disease.

Improvement of Lung Function

Supports sustained airway patency during long-term treatment.

Here are the benefits of Maxiflo 125 6mcg Inhaler 120mdi:

• Dual mechanism in one inhaler: Combines anti-inflammatory and bronchodilator actions.

• Improves long-term asthma control: Reduces symptom frequency and airway inflammation.

• Provides sustained bronchodilation: Formoterol keeps airways open for prolonged periods.

• Reduces exacerbation risk: Helps lower frequency of acute respiratory worsening.

• Improves breathing comfort: Reduces wheezing, chest tightness, and breathlessness.

• Supports better treatment adherence: Single inhaler simplifies therapy.

Like all medicines, Maxiflo 125 6mcg Inhaler 120mdi may cause side effects in some individuals, although many patients tolerate it well when inhaler technique is correct.

Common Side Effects

• Throat Irritation: Mild throat discomfort may occur after inhalation.

• Hoarseness of Voice: Local steroid deposition may affect vocal cords.

• Oral Thrush: Fungal infection may develop if mouth rinsing is neglected.

• Headache: Mild headache may occur in some individuals.

• Tremor: Formoterol may cause fine hand tremors.

Uncommon Side Effects

• Palpitations: Mild awareness of heartbeat may occur.

• Dry Mouth: Some individuals experience dryness.

• Cough After Inhalation: Temporary cough may occur immediately after use.

Serious Side Effects (Require Immediate Medical Attention)

• Paradoxical Bronchospasm: Sudden worsening of breathing after inhalation requires urgent medical attention.

• Severe Allergic Reaction: Swelling, rash, or breathing difficulty requires emergency care.

• Marked Tachycardia: Rapid heartbeat requiring medical review.

Always consult your doctor if side effects persist or worsen.

To ensure effective inhalation therapy:

• Use exactly as prescribed.

• Shake inhaler if required by device type.

• Exhale fully before inhalation.

• Inhale slowly and deeply while activating the inhaler.

• Hold breath for several seconds after inhalation.

• Rinse mouth after each use.

• Do not exceed prescribed doses.

Maxiflo 125 6mcg Inhaler 120mdi works through two complementary mechanisms.

Formoterol selectively stimulates beta-2 adrenergic receptors in bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cyclic AMP. This causes relaxation of airway smooth muscle and prolonged bronchodilation.

Fluticasone Propionate binds to intracellular glucocorticoid receptors in airway cells and suppresses transcription of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. This reduces airway inflammation, mucus production, and bronchial hyperresponsiveness.

Together, the combination provides sustained bronchodilation and long-term anti-inflammatory control.

• Always rinse mouth after inhalation.

• Use inhaler regularly even if symptoms improve.

• Check inhaler technique periodically.

• Carry rescue inhaler if separately prescribed.

• Avoid known airway triggers.

• Store below 25°C

• Keep away from direct heat

• Keep inhaler cap closed

• Keep out of reach of children

Maxiflo 125 6mcg Inhaler 120mdi does not have major food interactions. However:

• Avoid excessive caffeine intake: Large amounts of tea, coffee, energy drinks, or caffeinated beverages may increase palpitations, tremors, or nervousness in sensitive individuals because Formoterol can stimulate the cardiovascular system.

• Maintain adequate hydration: Good hydration helps maintain airway moisture and may improve overall respiratory comfort, particularly in dry environments.

• Avoid smoking: Smoking reduces the effectiveness of inhaled corticosteroids and may worsen airway inflammation, making long-term disease control more difficult.

• Follow a balanced diet: Proper nutrition supports respiratory health and overall treatment outcomes in chronic airway disease.

Fluticasone Propionate + Formoterol may interact with:

• Beta-Blockers: These medicines may reduce the bronchodilator effect of Formoterol and may provoke bronchospasm in susceptible individuals.

• Other Beta-2 Agonists: Concurrent use may increase the risk of tremor, palpitations, and excessive sympathetic stimulation.

• Diuretics: Certain diuretics may increase the risk of hypokalaemia when used with Formoterol.

• Xanthines (e.g. theophylline): Combined use may enhance cardiovascular side effects and potassium loss.

• MAO Inhibitors: May potentiate the cardiovascular effects of Formoterol and require caution.

• Strong CYP3A4 Inhibitors (e.g. ketoconazole, ritonavir): These may increase Fluticasone exposure and raise the risk of systemic steroid effects.

• Systemic Corticosteroids: Combined prolonged use may increase total corticosteroid exposure and associated side effects.

Maxiflo 125 6mcg Inhaler 120mdi should be used carefully in:

• Cardiac Arrhythmias: Formoterol may increase heart rate or worsen rhythm disturbances in susceptible individuals.

• Ischaemic Heart Disease: Beta-2 stimulation may increase cardiac workload in sensitive patients.

• Hyperthyroidism: Sympathomimetic effects of Formoterol may be more pronounced in patients with thyroid overactivity.

• Diabetes Mellitus: High doses may affect blood glucose levels and require periodic monitoring.

• Hypokalaemia: Beta-2 agonists may lower potassium levels further, especially in patients already at risk.

• Glaucoma: Inhaled corticosteroids used for prolonged periods may contribute to increased intraocular pressure in predisposed individuals.

The dose depends on disease severity, inhaler strength, and patient response. It is usually taken 1–2 inhalations daily as prescribed.

If you miss a dose, take it when remembered unless the next dose is due soon. Do not double the dose.